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Abstract
Introduction. Chronic venous diseases are one of the urgent problems of modern medicine. Recent studies have shown 
high significance of endothelial dysfunction (ED) and oxidative stress in their pathogenesis. For the correction of the 
occurring changes, drugs of the flavonoid group, particularly diosmin and hesperidin, are currently used. Numerous 
studies have confirmed a vast range of biological effects of diosmin; however, there are only sporadic data on its endo-
thelium protective effects.
Materials and methods. The study was performed in 70 white mature male rats of Wistar line, weighing 180-220 g. 
ED simulation was performed using non-selective blocker of NO-synthase N-nitro-L-arginine methyl ester (L-NAME). 
Functional vascular tests and biochemical markers were used to determine a degree of correction of functional disor-
ders. An anti-inflammatory effect of Detralex 1000 mg was estimated in 10 mature albino rabbits weighing 2800 - 3200 
g by using o-xylene. The study of the venotonic property of the drug was carried out in the experiment in an isolated 
segment of the rats’ portal vein with Ca2+ solutions at a concentration of 0.08-1.75 mcM. The histologic specimens were 
prepared in accordance with the generally accepted methods.
Results and discussion. The administration of the test drug did not lead to a statistically significant decrease in blood 
pressure in the conditions of L-NAME-induced ED. However, there was a dose-dependent statistically significant 
decrease in the coefficient of ED (CED), which indicates a positive endothelium protective effect. Course administra-
tion of Detralex 1000 mg leads to a significant dose-dependent correction of platelet aggregation disorders, which is 
manifested in the extended aggregation time. The results of studying an anti-inflammatory activity of the drug showed 
a decrease in the size of spots caused by the application of o-xylene, and the extention of the time interval before their 
onset. Studying a Ca2+-mediated smooth muscle response showed that the vein contractile force reaches its maximum 
at a higher dosage of the drug with a lower concentration of Ca2+. In the morphological study of the stomach wall, 
small and large intestine of the intact rats and rats receiving a course of Detralex 1000 mg, there were no inflammatory 
changes in the mucosa of the comparison group.
Conclusions. The study found that Detralex 1000 mg significantly reduces the ED coefficient and slows platelet ag-
gregation against the background of L-NAME-induced ED; the efficacy is dose-dependent. Detralex 1000 mg dose-de-
pendently reduces vascular permeability disorders caused by the application of o-xylene. The test drug has a Ca2+-me-
diated mechanism of increasing the contractile activity of the venous wall. It was found that the course administration 
of the drug per os has no local irritative effect.
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Introduction
Chronic venous diseases are one of the urgent problems 
of the modern medicine (Naess et al. 2007, Spencer et al. 
2009). Recent studies have shown the high importance 
of endothelial dysfunction (ED) and oxidative stress in 
their pathogenesis (Nebylitsin et al. 2008, Castro-Fer-
reira et al. 2018). In the walls of the vessels involved in 
the pathological process, there is an increased producti-
on of proinflammatory cytokines: IL-6, IL-8, MMP-31 
and proteolytic enzymes, adhesion molecules, and accu-
mulation of lipid peroxidation products (Lattimer et al. 
2016, Denisiuk 2017). In addition, there is an increase 
in the adhesive properties of platelets and leukocytes 
to the endothelium, with the latter further migrating the 
into the vessel wall (Khadieva et al. 2016). The resulting 
vein-specific inflammation leads to a violation of endo-
thelial function and permeability of the vascular wall 
(Aliev et al. 2008, Kudryavtsev et al. 2017). The final of 
the subsequent complex of pathophysiological events is 
disruption of the venous wall tone and its morphological 
structure (Raffetto 2018).
The flavonoid group of drugs, particularly those con-
taining diosmin and hesperidin, is actively used nowadays 
for the correction of venous tone and reduction of the core 
symptoms of chronic venous insufficiency (Belcaro et al. 
2002, Boisseau 2002). Numerous studies have confirmed 
a wide range of biological effects of diosmin, including its 
anti-ulcer, antimutagenic, antioxidant, and anti-inflamma-
tory effects (Benavente-Garcia and Castillo 2008, Gracas 
et al. 2018). Antioxidant effects of Detralex are connected 
with the inhibition of endothelin-1 synthesis and direct 
reduction of the production of prostaglandin E2, F2 and 
thromboxane A2 (Manthey 2000, Feldo et al. 2018, Pi-
etrzycka et al. 2015).
There is evidence of increased pressor effects of Ca2+ 
by diosmin (Savineau and Marthan 1994). It is also found 
that diosmin affects alpha- and beta-2-adrenoreceptors 
and, like endogenous catecholamines, increases the tone 
of the venous vessels (Borisova et al. 2008).
Treatment of chronic venous pathology with flavo-
noid preparations implies their long-term course admin-
istration per os (up to 6 months), which makes the issue 
of their possible local toxic effect relevant (Stoyko and 
Gudymovich 2006). 
Objective: to evaluate experimentally the pharmaco-
logical correction of ED, vascular permeability, platelet 
aggregation and venous tone with diosmin Detralex 1000 
mg, as well as to assess its local irritative effect in the 
course of treatment.
Materials and methods
The test drug is Detralex 1000 mg (France, Servier), 
which is a micronized purified fraction of flavonoids con-
taining 90% of micronized diosmin (900 mg) and 10% of 
flavonoids in terms of hesperidin (100 mg), with a maxi-
mum fractionation of the substance to particles with a di-
ameter of <2 microns, which makes it possible to improve 
the absorption of the substance (Garner et al. 2002).
The ED simulation was performed in 40 white male rats 
of Wistar line weighing 180–220 g. Non-selective blocker 
of NO-synthase N-nitro-L-arginine methyl ester (L-NA-
ME) was administered intraperitoneally at a dose of 25 
mg/kg/day for seven days. On the 7th day under anesthesia 
(chloral hydrate 300 mg/kg), a catheter was inserted into 
the left carotid artery to record hemodynamic parameters. 
The hemodynamic parameters: systolic blood pressure 
(SBP), diastolic blood pressure (DBP), and heart rate (HR) 
were measured continuously using a sensor and hardwa-
re for invasive measurement of hemodynamic parameters 
BIOPAC MP-150 (USA), with a TSD-104A module and 
computer software ASQKNOWLEDGE 4.2. Functional 
tests are the intravenous administration of acetylcholine 
(40 µg/kg) and sodium nitroprusside (30 µg/kg).
All the animals were divided into 4 groups: 1st group 
– intact rats treated with physiological solution in equivo-
lume doses, 2nd group – rats treated with L-NAME intra-
peritoneally for 7 days, 3rd - rats treated with NAME in-
traperitoneally + Detralex 1000 mg per os at the minimum 
therapeutic dose of 86 mg/kg/day for 7 days, 4th group 
– rats treated with L-NAME intraperitoneally + Detralex 
1000 mg per os at the maximum therapeutic dose of 260 
mg/kg/day for 7 days. The development of ED in the ex-
perimental animals, as well as the degree of its correction 
by the test drug, was estimated by the calculated coeffi-
cient of ED (CED) (Pokrovskii et al. 2006).
The level of NO metabolites (i.e. the total concentra-
tion of nitrates and nitrites, NOx) was determined colori-
metrically according to the stain intensity when using sul-
fanilamide nitrite, a component of Griess reagent, in the 
diazotization reaction (Metelskaya and Gumanov 2005).
Platelet aggregation was studied by visual microme-
thod using ADP, collagen, thrombin, ristomycin, and 
adrenaline as inducers.
To study the anti-inflammatory activity of the drug by 
Oivin’s method (Suleyman et al. 2001), the experiments 
were conducted in 10 adult albino rabbits weighing 2800–
3200 g. The rabbits were fixed, with the fur on the abdo-
men skin (the area of 13 cm) being cut off beforehand. 
During the study, the albino rabbits were administered 
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once Detralex 1000 mg at the maximum (100 mg/kg/day) 
and minimum (34 mg/kg/day) therapeutic doses 9 hours 
before the administration of the permeability indicator, 
namely Evans blue solution. The indicator of capillary 
permeability was the onset time of blue-colored spots on 
the skin and their diameter. 
To estimate Ca2+-dependent smooth muscle response, 
30 male rats of Wistar line were divided into 3 groups. 1st 
group – control, 2nd group – rats receiving Detralex 1000 
mg at the minimum therapeutic dose of 86 mg/kg/day, 3rd 
group – rats receiving Detralex1000 mg at the maximum 
therapeutic dose of 260 mg/kg per day. The drug was ad-
ministered per os once a day for 7 days. 
After the anesthesia (chloral hydrate 300 mg/kg), a 
portal vein preparation 25±4 mm long was taken from 
each animal. The preparation was placed vertically in the 
BIOPAC station reservoir for testing tissues (at an initial 
tension of 0.5 g). The lumen of the isolated vein was ligat-
ed, which excluded the contact of solutions with the endo-
thelium. The tests were performed with solutions of Ca2+ 
at a concentration of 0.08–1.75 mcM (Savineau and Mar-
than 1994). The solutions were added into the perfusate 
sequentially, from the minimum to the maximum concen-
tration of Ca2+. As the base solution, a modified Krebs–
Henseleit solution was used, in which the concentration 
of Ca2+ had been changed; isotonicity was achieved by 
changing the content of sodium chloride (all chemicals by 
Reakhem, Russia). The oxygenation of the solutions was 
performed by using a gas mixture of 95% O2 and 5% CO2.
The temperature of all the solutions was 30°C. Registra-
tion and processing of the data was performed using the 
BIOPAC ASQKNOWLEDGE 4.2 software.
To estimate the local irritative effect of Detralex 1000 
mg, a special morphological study of the stomach, small 
intestine and large intestine of rats treated with Detralex 
1000 mg at a maximum therapeutic dose of 260 mg/kg 
once a day for 7 days was performed.
The recovered organs were fixed in 10% formalin solu-
tion after macroscopic examination and weighing. The 
samples for histological examination were cut out from 
the stomach wall along the lesser curvature including  the 
cardiac part and a body area (glandular zone). 
In the standard mode, the material was embedded into 
paraffin in a spin  tissue processor “STP-120” (Microm 
International GMbH, Germany), using a battery of ethyl 
alcohol and xylene. The filling of blocks with standard 
orientation of samples was carried out in paraffin in Mi-
crom EC 350 embedding station (Microm International 
GMbH, Germany). To ensure the standardization, par-
affin embedding was carried out in multi-blocks of 5-6 
samples. The sections for histological examination of 5 
µm were cut on an HM 340 Е semi-automatic rotary mi-
crotome with slide feed and smoothing-out systems (Mi-
crom International GMbH, Germany). Hematoxilin and 
eosin staining was carried out in an automatic machine for 
staining histological sections and smears (Microm Inter-
national GMbH, Germany).
A descriptive study of histological specimens was 
performed using a AxioScopeA1 microscope (Carl Zeiss 
Microimaging GMbH, Germany). The main part of the 
morphological studies was performed after creating an 
electronic gallery of images by means of a semi-automat-
ic Miraz Desk slide scanner (Carl Zeiss Microimaging 
GMbH, Germany), which made it possible to standardize 
the modes of morphometric studies as much as possible. 
The scanner lens magnification was ×200. Digital magni-
fication in microphotographs and images during the anal-
ysis ranged from ×20 (without software magnification) to 
X800 (at 40-fold software magnification). All the studies 
were conducted in accordance with the principles of the 
Helsinki Declaration. 
Statistical processing of the results of the study was 
carried out by checking the data for the normality of dis-
tribution. The type of distribution was determined by the 
Shapiro-Wilk test. In the case of the normal distribution, 
the mean (M) and the standard error of the mean (m) were 
calculated. Intergroup differences were analyzed by para-
metric (Student’s t-test) or nonparametric (Mann-Whit-
ney U test) methods, depending on the type of distribu-
tion. All the calculations were performed using a package 
of MICROSOFT EXCEL 7.0.statistical software 
Results and discussion
With the administration of L-NAME, on the 7th day there 
was a statistically significant increase in systolic and di-
astolic blood pressure from 135.7±4.1 and 99.9±3.3 to 
188.3±6.1 and 143.0±2.9 mm Hg, respectively (Table 1), 
an increase in  CED from 1.2±0.1 to 5.0±0.6 (p<0.05) and 
a decrease in the final NO metabolites from 45.19±2.89 
to 22,69±1.50.




SBP, mm Hg DBP, mm Hg CED, relative unit (RU) NO, µmol/ml
Intact 135.7±4.1# 9.9±3.3# 1.2±0.1# 45.19±2.89 #
L-NAME 188.3±6.1* 143.0±2.9* 5.0±0.6 22.69±1.50*#
L-NAME + Detralex (86 mg/kg/day) 185.3±4.6* 134.1±3.4* 2.4±0.4*# 31.34±1.64*#
L-NAME + Detralex (260 mg/kg/day) 174.0±4.0* 135.3±3.2* 2.0±0.1*y 34.42±2.20*#
Note. * p<0.05 compared to intact rats; # – p<0,05 in comparison with L-NAME.
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The introduction of the test drug did not lead to a sta-
tistically significant decrease in blood pressure. However, 
there was a dose-dependent statistically significant de-
crease in CED, which indicates a positive endothelium 
protective effect. 
The administration of non-selective blocker of NO-syn-
thase causes a violation of platelet aggregation, which is 
expressed in its acceleration (Table 2). The introduction 
of  Detralex 1000 mg leads to a dose-dependent correc-
tion of disorders, which is manifested in the extension of 
platelet aggregation. It was found that in the maximum 
therapeutic dose the greatest efficacy of Detralex 1000 mg 
was observed when using adrenaline as an inducer: the 
extension of platelet aggregation time from 79.4±2.7 to 
96.9±3.9 sec.
The results of the studies of an anti-inflammatory ac-
tivity of the drug by Oivin’s method presented in Table 3 
indicate a decrease in the permeability of blood vessels 
with the introduction of the test drug, as evidenced by a 
decrease in the size of spots and the extension of the time 
interval of their onset. It should be noted that the use of 
Detralex 1000 mg at a dose of 260 mg/kg/day to a grea-
ter extent reduces the disruption of vascular permeability 
caused by the application of 0-xylene. 
In the study of the Ca2+-mediated smooth muscle res-
ponse, it was found that the addition of Ca2+ to the soluti-
on in the control group led to an increase in venous tone 
starting with a concentration of 0.76 mmol/l, while 7-day 
administration of Detralex 1000 mg caused a significant 
increase in venous tone with a Ca2+ concentration of 0.25 
mmol/l. At the same time, against the background of the 
course treatment with Detralex 1000 mg, the sensitivity 
of the venous smooth muscle wall to Ca2+ at a concentra-
tion of 0.76 mmol/l is significantly higher than that in the 
control. The effect of the drug is dose-dependent, which is 
manifested in reaching the maximum contractile force at 
a higher dosage of the drug with a lower concentration of 
Ca2+. This is most clearly demonstrated in Figure 1.
The morphological study of the stomach wall of in-
tact rats and rats against treating them with Detralex 
1000 mg for 7 days at a dose of 260 mg/kg daily found 
no inflammatory changes in the mucosa of the compa-
rison group. The general structure of the stomach wall 
is normal (Fig. 2). In the transition zone, there is a clear 
boundary between the non-keratinized stratified squa-
mous epithelium of the esophagus and the fundal-type 
glandular mucosa. Glandular mucosa is 420-470 µm 
thick, and the pits are distributed evenly, with smooth 
contours, 90-110 µm deep, lined with a monomorphic 
single layer of columnar epithelium. On the surface, the-
re is a moderate amount of mucus. The fundal glands 
evenly fill the thickness of the mucous membrane, with 
clearly differentiated areas: the surface part of 150-180 
microns long, formed mainly with mucous and parietal 
cells, the bottom part of the same length, formed mainly 
with adeloniorphous cells. Parietal cells are with homo-
geneous oxyphilic cytoplasm, the main ones are with 
basophilic moderately granulated cytoplasm. No nuclear 
change is defined. The layers of lamina propria between 
the glands are thin; no significant leukocyte infiltration 
is determined. No changes were detected on the part of 
Table 3. Effect of Detralex 1000 mg on Vascular Permeability (M±m; n=10).
Group Average area of the spots, cm2 Time of spot onset, sec
Control 6.58±0.08 202±6.11
Detralex 1000 mg (86 mg/kg/day) 5.20±0.06* 243±7.30*
Detralex 1000 mg (260 mg/kg/day) 4.38±0.05* 290±6.15*
Note. * – p<0.05 in relation to the control group.




ADP, sec collagen, sec ristomycin, sec adrenaline, sec
Intact 43.6±1.5# 33.0±0.6# 41.5±1.9# 102.4±3.8#
L-NAME 30.2±1.3* 27.1±1.1* 31.6±1.2* 79.4±2.7*
L-NAME + Detralex (86 mg/kg/day) 34.6±1.5* 31.5±1.0# 36.2±1.5# 92.3±3.9#
L-NAME + Detralex (260 mg/kg/day) 35.2±1.4# 32.1±1.0# 37.2±1.36# 96.9±3.9#
Note. * – p<0.05 compared to intact rats; # – p<0,05 in comparison with L-NAME.
Figure 1. Effect of Detralex 1000 mg on contractility of isolated 
segment of rat portal vein.
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Figure 4. Colon after 7-day administration of Detralex 1000 mg 
at a dosage of 260 mg/kg/day with the structure of all mem-
branes corresponding to that of the intact. There were no inflam-
matory changes in the lamina propria. Staining with hematoxy-
lin and eosin. Microphoto. ×200 (digital). 
Figure 2. Histological structure of gastric mucosa after 7-day 
administration of Detralex 1000 mg at a dosage of 260 mg/kg/
day. Glandular zone of the mucous membrane is without visible 
morphological changes, no inflammatory changes. Staining with 
hematoxylin and eosin. Microphoto. ×200 (digital).
Figure 3. The structure of the wall of the jejunum after 7-day 
administration of Detralex 1000 mg at a dosage of 260 mg/kg/
day: the mucous membrane is of the usual structure, no visible 
morphological changes, no inflammatory changes. Staining with 
hematoxylin and eosin. Microphoto. ×200 (digital).
other membranes of the wall. Blood content of all the 
membranes is moderately equal.
Histological examination of the small intestine of rats 
after the course treatment with Detralex 1000 mg at a 
dose of 260 mg/kg daily, neither inflammatory nor atrop-
hic changes of the small intestine mucosa were identified 
(Fig.3). The villi of the mucous membrane are covered 
with columnar epithelium. In the bottom parts of the 
crypts, there are numerous mitotically dividing epithelial 
cells. In the stroma of the villi, there are many plasma 
cells, sometimes with an admixture of eosinophils.
Estimating the condition of the mucous membrane 
of the large intestine of rats treated with Detralex 1000 
mg for 7 days at a dose of 260 mg/kg daily, neither in-
flammatory nor dystrophic changes were recorded (Fig. 
4). The intestinal mucosa is covered with columnar 
epithelium. There are numerous mitotically dividing 
epithelial cells. 
The results of microscopic examination of the internals 
of rats receiving the test drug showed that Detralex 1000 
mg does not cause either dystrophic, inflammatory or other 
pathological changes of the internals in the test dosage. 
According to a number of studies, besides the resto-
ration of NO synthesis, an endothelium-protective effect 
of diosmin is mediated by an increase in the activity of 
antioxidant enzymes, in particular superoxide dismutase 
(Cotelle  2001, Wang et al. 2006). This creates the con-
ditions for the restoration of antioxidant balance in the 
endothelium and prevents its further damage. 
Other studies have also shown that diosmin reduces the 
synthesis of endothelin-1, which causes the proliferation of 
smooth myocytes and has a pronounced pro-inflammatory 
effect (Pietrzycka et al. 2015). In particular, it induces the 
synthesis of integrins that enhance the migration and adhe-
sion of fibroblasts and platelets, increases vascular permea-
bility, activates neutrophils, mast cells and T-lymphocytes, 
which leads to the release of pro-inflammatory cytokines, 
mediators and the launch of the leukocyte-endothelial cas-
cade. Mediators of inflammation – prostaglandin E2 and 
thromboxane A2, in their turn, increase platelet aggregati-
on and have a powerful pro-coagulant effect (Tyurenkov et 
al. 2012). In addition to inhibiting the synthesis of endot-
helin-1, there is evidence of a direct influence of diosmin 
on a decrease in the production of prostaglandin E2, F2 and 
thromboxane A2, which also causes its anti-inflammatory 
effect (Manthey 2000, Feldo et al. 2018).
The extension of platelet aggregation rate in the ex-
periment in a group of animals receiving Detralex 1000 
mg against the background of simulated ED is due to the 
restoration of NO synthesis, which is a natural disaggre-
gation (Tyurenkov et al. 2012). 
The results of the experiment to study the venotonic 
effect of diosmin suggest a dose-dependent increase in 
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sensitivity of the segment of the portal vein with isolated 
endothelium to Ca2+ in the course treatment with Detralex 
1000 mg. A number of studies have shown that such an 
increase in sensitivity of smooth myocytes to Ca2+ is also 
influenced by phosphatase inhibitors (Gong et al. 1992) 
or agonists of alpha-adrenergic receptors (Kitazawa et al. 
1991). In the case of alpha-adrenergic receptors, incre-
ased sensitivity is most likely associated with G-proteins, 
which implies accelerated phosphorylation of the myosin 
component of the chains (Nishimura et al. 1990).
Conclusion
According to the results of studying an endothelium-pro-
tective activity of Detralex, 1000 mg, it was established 
that the test drug significantly reduces  СED and slows 
the aggregation of platelets against the background of ED 
simulation. It should be noted that the efficacy of endo-
thelium-protective action of the drug is dose-dependent.
The results of studying the data on the effect of Detralex 
1000 mg on vascular permeability suggest that the drug 
can dose-dependently reduce vascular permeability disor-
ders caused by the application of o-xylene.
Detralex 1000 mg has a Ca2+-mediated mechanism of 
increasing the contractile activity of the venous wall.
Detralex 1000 mg, when intragastrically adminis-
tered to rats at a maximum therapeutic dose of 260 
mg/kg/day, does not lead to either macroscopic or his-
tological changes in the stomach, small intestine and 
large intestine, therefore does not have a local irrita-
tive effect.
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